Razi Cov Pars
Razi Cov Pars (Persian: رازی کوو پارس) is a COVID-19 vaccine developed by the Iranian Razi Vaccine and Serum Research Institute.[1][2][3]
 | |
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Protein subunit |
| Clinical data | |
| Routes of administration | Intramuscular, Intranasal |
| Legal status | |
| Legal status | |
| Part of a series on the |
| COVID-19 pandemic |
|---|
 Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom. |
|
.svg.png.webp){kind=small} COVID-19 portal |
It's the second Iranian COVID-19 vaccine reaching human trials[1] and is currently in phase III of clinical research during which it's compared to the Sinopharm BIBP vaccine.[4][5] It received emergency use authorization in Iran on 31 October 2021.[6][7]
Medical uses
It requires three doses given day 0 (intramuscular), day 21 (intramuscular) and day 51 (intranasal spray).[3]
Pharmacology
Razi Cov Pars is a recombinant protein subunit vaccine containing the SARS-CoV-2 spike protein.[2]
Manufacturing
It's planned to produce one million doses of the vaccine each month as of September 2021.[4]
As of 25 November 2021, 5 millions doses have been delivered to the Iranian Ministry of Health.[8]
History
Clinical trials
| Phase | Registration number | Start | Number of participants | Age of participants | Ref | ||
|---|---|---|---|---|---|---|---|
| Total | Vaccine | Placebo | |||||
| I | IRCT20201214049709N1 | 21 January 2021 | 133 | 30 (5 µg/200µL)
30 (10 µg/200µL) 30 (20 µg/200µL) |
30 (placebo)
13 (sentinel) |
18-50 years | [2] |
| II | IRCT20201214049709N2 | 13 April 2021 | 500 | 18-70 years | [3] | ||
| III | IRCT20201214049709N3 | 29 August 2021 | 41,128 | 20,564 | 0 (placebo)
20,564 (Sinopharm BIBP vaccine) |
18+ years | [5] |
References
- Mehdi SZ (7 February 2021). "Iran unveils second homegrown COVID-19 vaccine". Anadolu Agency. Retrieved 22 April 2021.
- "Phase I, Safety and Immunogenicity of Razi SARS-CoV-2 recombinant Spike protein vaccine (Razi Cov Pars), in healthy adults aged 18-55 years; parallel 4 arms design (adjuvant only and three vaccine doses of 5, 10, and 20 µg/200µl); a Randomised, double blind, clinical trial". irct.ir. Iranian Registry of Clinical Trials. Retrieved 21 March 2021.
{{cite web}}: CS1 maint: url-status (link) - "Phase II, Safety and Immunogenicity of RAZI SARS-CoV-2 recombinant Spike protein vaccine (RAZI Cov Pars) in adults aged 18-70 years; a Randomised, double blind, parallel 2 arms clinical trial". Iranian Registry of Clinical Trials. Retrieved 22 April 2021.
{{cite web}}: CS1 maint: url-status (link) - "COVID-19 vaccine Razi Cov Pars starts third clinical trial phase". Tehran Times. 27 August 2021. Retrieved 30 August 2021.
- "IRCT | Comparison of the safety and efficacy of Razi SARS-CoV-2 recombinant Spike protein (Razi Cov Pars) and Sinopharm vaccines in adults aged 18 and over, a phase III randomised, double blind, non-inferiority clinical trial". en.irct.ir. Retrieved 30 August 2021.
- "مجوز مصرف اضطراری داوطلبانه واکسن کووپارس صبح امروز صادر شد" [Voluntary emergency use of Koopars vaccine was issued this morning]. ایسنا (ISNA) (in Persian). 31 October 2021. Retrieved 27 November 2021.
- "Two homegrown vaccines receive emergency use license". Tehran Times. 1 November 2021. Retrieved 27 November 2021.
- "۵ میلیون دز واکسن رازی به وزارت بهداشت تحویل داده شد" [5 million doses of Razi vaccine were delivered to the Ministry of Health]. ایسنا(ISNA) (in Persian). 25 November 2021. Retrieved 27 November 2021.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.